Market Revenue Prostate Cancer Medicine Industry Share, Price | Página 2

types, applications, and region. Types such as Targeted Therapy Drugs, Hormonal Therapy Drugs,
Immunotherapy Drugs, and Chemotherapy Drugs classify Prostate Cancer Medicine Industry.
Targeted Therapy Drugs consists of Signal transduction inhibitor - Sprycel, Angiogenesis inhibitor -
lanreotide, TASQ, Zaltrap, and Apoptosis inducing - custirsen sodium. Hormonal Therapy Drugs
consists of Pipeline drugs - Zytiga, MDV3100, and TAK700, LHRH antagonists - Firmagon,
Antiandrogens - Casodex, and LHRH analogs - Zoladex, Lupron, Eligard, Vantas, and Decapeptyl.
Hormonal Therapy segment accounts for the largest market share of Prostate Cancer Medicine
Market and is estimated to lead the overall market in the years to come. The reason being, the
presence of a significant number of recognized drugs like AbbVie’s Lupron and Astra Zeneca’s Zoladex.
In addition, the effectiveness of these drugs in treating prostate cancer is another factor rising the
growth of the market. Applications into Pharmacy, Hospital, and others classify this market.
Prostate Cancer Medicine Market is segmented geographically into Americas (North America, Latin
America), Europe (Eastern Europe, Western Europe), Asia Pacific, Latin America, Middle East and
Africa. Globally, Americas accounts for the largest market share of Prostate Cancer Medicine Industry
and is estimated to lead the overall market in the years to come. The reason being, the presence of
key manufacturers in the region, high demand for targeted therapies and immunotherapies in the
United States, developed healthcare infrastructure, and growing awareness among individuals
regarding prostate cancer. The United States is the major consumer of this market in this region.
Europe and Asia Pacific follow suit.
Request Sample Copy of Prostate Cancer Medicine Industry @
https://www.millioninsights.com/industry-reports/prostate-cancer-medicine-market/request-sample
On the other hand, Asia Pacific is estimated to grow at fastest pace in the years to come. The reason
being, a government initiative in generating awareness through online portals and programs that
gives details regarding screening & diagnosis through PSA blood tests and DRE for male patients over
50 years of age. In addition, increasing investments by manufacturers for the development of
immunotherapies and targeted therapies, use of modern technologies, and improving healthcare
infrastructure.
The key players of Prostate Cancer Medicine Market are Roche Holding AG, AstraZeneca Plc., Astellas
Pharma AG, Active Biotech, Abbott Laboratories, Bristol Myers - Squibb, Bayer AG, Teva
Pharmaceuticals Industries Ltd., Pfizer Inc., and Johnson & Johnson. These players are concentrating